• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
Gaucher Disease Market Size & Share, 2025 | Industry Growth Report

Gaucher Disease Market Size, Status and Forecast 2025

Report ID: MN17613368  |  Published: August 2016  |  No of Pages: 94
Format: Electronic (PDF)  |  Industry: Pharmaceuticals  |  Publisher: QY Research

Global Gaucher Disease Market is classified on the basis of product type, type of treatment molecules, route of administration, dosage forms, end users, and geography. A rare inherited disorder that results from the deficiency of the enzyme glucocerebrosidase is known as Gaucher disease. The typical character of this disease is that there is deposition of fatty substances in body’s organs and tissues.

The signs and symptoms of Gaucher disease may differ widely among people. Some of the signs and symptoms of Gaucher disease include fatigue, enlarged liver and spleen, low platelet and haemoglobin counts,bone pain and fractures, etc. The diagnosis of Gaucher disease can be carried out by laboratory testing either by quantifying the level of the enzyme glucocerebrosidase or by DNA study of the GBA gene for the four most common GBA mutations.

There are mainly three types of Gaucher disease. The mildest and most common type of Gaucher disease is Type 1. The type 1 disorder is also known as Nonneuronopathic Gaucher disease and it does not affect the nervous system.

Whereas, neuronopathic forms of Gaucher disease are Type 2 also called as acute infantile neuronopathic Gaucher disease and Type 3 also called as chronic neuronopathic Gaucher disease. These types of disorder affect the central nervous system and cause severe problems brain damage, seizures, respiratory problems, poor development, eye movement disorders, enlarged spleen & liver, bone problems, etc.

Gaucher Disease is also known as glucosylceramide lipidosis, cerebrosidelipidosis syndrome, kerasinlipoidosis, glucocerebrosidase deficiency, kerasinhistiocytosis, glucosylceramide beta-glucosidase deficiency, Gaucher splenomegaly, glucosylceramidase deficiency, Gaucher syndrome, glucocerebrosidosis, lipoid histiocytosis (kerasin type), Gaucher's disease, GD, glucosylcerebrosidelipidosis and kerasinthesaurismosis.

The factors that propel the growth of the Gaucher Disease Market include increasing research & development activities and specialfacility for orphan drugs. On the other hand, there are also factors that may hamper the growth of the market such asinadequate patient population as it is a rare disease. Gaucher Disease Market is classified on the basis of product type asenzyme replacement therapy and substrate reduction therapy.

Gaucher Disease Market is classified on the basis oftype of treatment molecules as biologics, small molecules and others. Gaucher Disease Market is classified on the basis of route of administration asoral, and parenteral. Gaucher Disease Market is classified on the basis of dosage forms as solid, liquid and others.

Gaucher Disease Market is classified on the basis of end users as Non-neuronopathic Gaucher disease and Neuronopathic Gaucher disease. Gaucher Disease Market is classified on the basis of as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan and Middle East and Africa.

The North American region consists of the U.S., and Canada. Latin America region consists of Mexico and Brazil. The Western European region consists of Germany, Italy, France, England and Spain. The Eastern European region consists of Poland and Russia. Asia Pacific region consists of China, India, ASEAN, Australia & New Zealand. The Middle East and Africa region consists of GCC, South Africa and North Africa. Some of the key players that fuel the growth of the market include Actelion Pharma, Pfizer, Sanofi, Shire, and others.

Market Segment:

This report studies the global Gaucher Disease market, analyzes and researches the Gaucher Disease development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
• Sanofi
• Shire
• Actelion Pharma
• Pfizer
• ISU Pharm

Market segment by Regions/Countries, this report covers
• United States
• EU
• Japan
• China
• India
• Southeast Asia

Market segment by Type, the product can be split into
• Enzyme Replacement Therapy
• Substrate Reduction Therapy

Market segment by Application, Gaucher Disease can be split into
• Non-Neuronopathic Gaucher Disease
• Neuronopathic Gaucher Disease

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available